For nearly half of people diagnosed with lung cancer, immunotherapy can slow the disease but not stop it. Funded through a $4 million joint investment from the Canadian Cancer Society (CCS) and the Weston Family Foundation, a new clinical trial aims to change that.
Venetoclax and HMA-based Therapies for the Treatment of Older and Unfit Adults with Newly Diagnosed FLT3-mutated AML: A myeloMATCH Substudy
VIGOR: Vorasidenib as Maintenance Treatment after First-line Chemoradiotherapy in IDH-mutant Grade 2 or 3 Astrocytoma
Autologous Stem Cell Transplant in Peripheral T Cell Lymphoma that Achieved a First Complete Remission (CR1) Following Induction Therapy (PTCL-STAT)
Lanreotide for the Prevention of Postoperative Pancreatic Fistula
A new survey study SC32S, collecting sociodemographic data from clinical trial participants, has now opened across Canada. This study will help researchers understand the feasibility of using a survey to gather information about trial participants’ backgrounds and everyday lives.
Phase II Trial of ASTX727 and Venetoclax Compared with ASTX727, Venetoclax, and Enasidenib for New Diagnosed Older Adults with IDH2 Mutant AML - A myeloMATCH Substudy
Eradicating MRD in Patients with AML prior to Stem Cell Transplant (ERASE)
Investigating Precision Medicine in the Adjuvant setting: a phase III Clinical Trial in Biliary tract cancer (SAFIR IMPACT BTC)
LUNA-2: LND101 in Unresectable Non-Small Cell Lung Cancer: A Randomized Phase II Trial
Induction Pembrolizumab and Chemotherapy Followed by Chemoradiation and Pembrolizumab vs Chemoradiation and Pembrolizumab Both Followed by Pembrolizumab for High Risk Locally Advanced Cervical Cancer
RAINBO-ORANGE: Treatment of Endometrial Cancer Based On Molecular Features
The next CCTG Clinical Research Associate (CRA) Lunch and Learn training session will be on Wednesday Jun 24th, 2025, at 12 pm ET, covering the top
Dr. Jonathan Loree has been recognized for his Phase III research contributions with the CCTG 2022 Dr. Ralph Meyer Phase III Young Investigator Award.
CCTG congratulates BC Cancer Vancouver GCC1 Trial Team whose work was recognized with the 2022 CCTG Phase III Team Award, for performance in trial accrual, local activation timelines, compliance metrics and team performance.
The Dr. Joseph Pater Founder’s Award has been presented to Dr. Warren Mason, MD, FRCPC for his excellence in clinical trials research, leadership and his body of work that has contributed to significant advances in the understanding, diagnosis, treatment, cure, and prevention of cancer.
CCTG congratulates the Hotel-Dieu du Quebec MA39 trial team for their CCTG Phase III Team Award presented at the CCTG 2022 Spring Meeting.
The award is given to trial teams from member centres for performance in trial accrual, local activation timelines, compliance metrics and team performance. The team includes, Alexandre Villeneuve-Gauthier, Josee Allard, Dr. Valerie Theberge, Sophie Pouliot, Isabelle Desrosiers.
Dr. Aly-Khan A. Lalani, B.Sc (Hons), MD, FRCPC, has been awarded the 2022 CCTG Dr. Elizabeth Eisenhauer Early Drug Development Young Investigator Award recognizing his work as a new investigator who has contributed significantly to the conduct of an IND trials.
The Allan Blair Cancer Centre IND234 trial team has been awarded the 2022 CCTG IND Team Award for performance in trial accrual, local activation timelines, and compliance metrics, team performance.
CCTG is currently seeking volunteer Patient Representatives for the Brain Disease Site Committee (brain cancer) as well as for the Head and Neck Disease Site Committee (cancer inside the nose, throat or mouth). Patient Representatives participate in all aspects of disease site committee activities and are members of the CCTG Patient Representative Committee.
